Last reviewed · How we verify
PRGF-Endoret
At a glance
| Generic name | PRGF-Endoret |
|---|---|
| Sponsor | Biotechnology Institute IMASD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Autologous Platelet Concentrate (APC) in Intrabony Defects (NA)
- Influence of PRGF (Plasma Rich in Growth Factors) Puncture in Ovaries With Low Follicular Reservetechniques (PHASE3)
- Plasma Rich in Growth Factors in Post-extraction Sockets (NA)
- Plasma Rich in Growth Factors in the Preservation of the Alveolar Ridge After Simple Molar Tooth Extractions. (PHASE3)
- Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla. (PHASE3)
- Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis (PHASE4)
- Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia (NA)
- PRGF-ENDORET® Infiltrations in the Treatment of Low Back Pain. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRGF-Endoret CI brief — competitive landscape report
- PRGF-Endoret updates RSS · CI watch RSS
- Biotechnology Institute IMASD portfolio CI